Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease: A Randomized Controlled Trial

Article Abstract:

Purified poloxamer 188 may reduce the duration of a crisis episode in sickle cell patients, according to a study of 255 patients. This substance is given intravenously, and it supposedly prevents blood cells from clumping together.

Polymers

---

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

Article Abstract:

Hydroxyurea treatment for patients with sickle cell disease can lower their mortality rate by as much as 40%, according to a study of 299 patients. Patients who developed acute chest syndrome or vaso-occlusive events had higher mortality rates than those who did not. Hydroxyurea increases blood levels of fetal hemoglobin, which partly compensates for the abnormal hemoglobin that causes sickle cell disease.

Evaluation, Patient outcomes, Mortality, Prognosis, Drug therapy, Hydroxyurea

---

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography

Article Abstract:

Blood transfusions on a regular basis can substantially lower the risk of stroke in children with sickle cell anemia. Researchers randomly assigned 130 sickle cell patients with a high risk of stroke to receive standard care or regular transfusions to keep their hemoglobin S concentration less than 30%. Transfusions were required every three to four weeks. The trial was halted about one year after it began because 10 patients who received standard care had a stroke, compared to only one patient in the transfusion group.

Prevention, Stroke (Disease), Stroke, Blood transfusion

Similar abstracts:

• Abstracts: Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. Causes and outcomes of the acute chest syndrome in sickle cell disease
• Abstracts: Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy
• Abstracts: Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks
• Abstracts: Quality indicators for dementia in vulnerable community-dwelling and hospitalized elders. Quality indicators for the management of osteoarthritis in vulnerable elders
• Abstracts: Quality indicators for the management and prevention of falls and mobility problems in vulnerable elders. Quality indicators for prevention and management of pressure ulcers in vulnerable elders

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.